Kewaunee Scientific (KEQU) EBITDA (2010 - 2026)

Kewaunee Scientific's EBITDA history runs 17 years deep, the most recent figure standing at $5.2 million for Q2 2026.

• On a quarterly basis, EBITDA fell 38.64% year-over-year to $5.2 million in Q2 2026; TTM through Apr 2026 was $16.7 million, a 5.88% decrease from a year earlier, with the FY2026 full-year figure at $16.7 million, down 5.88% from the prior year.
• EBITDA climbed to $5.2 million in Q2 2026 per KEQU's latest filing, from $2.6 million in the prior quarter.
• Across five years, EBITDA topped out at $8.5 million in Q2 2025 and bottomed at -$868000.0 in Q1 2022.
• The 5-year median for EBITDA is $3.3 million (2023), against an average of $3.3 million.
• Across the five-year window, EBITDA slumped 130.85% in 2022 and surged 1061.62% in 2023, its largest moves.
• Year by year, EBITDA stood at $755000.0 in 2022, then soared by 576.69% to $5.1 million in 2023, then dropped by 13.21% to $4.4 million in 2024, then retreated by 7.37% to $4.1 million in 2025, then gained by 27.0% to $5.2 million in 2026.
• Per Business Quant, the three latest KEQU EBITDA figures stand at $5.2 million (Q2 2026), $2.6 million (Q1 2026), and $4.1 million (Q4 2025).